Bio-Rad Laboratories, Inc.
BIO · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $9,269 | $9,431 | $12,524 | $22,539 |
| - Cash | $488 | $404 | $434 | $471 |
| + Debt | $1,375 | $1,406 | $1,388 | $223 |
| Enterprise Value | $10,155 | $10,433 | $13,478 | $22,292 |
| Revenue | $2,567 | $2,671 | $2,802 | $2,923 |
| % Growth | -3.9% | -4.7% | -4.1% | – |
| Gross Profit | $1,379 | $1,427 | $1,567 | $1,638 |
| % Margin | 53.7% | 53.4% | 55.9% | 56.1% |
| EBITDA | -$2,142 | -$655 | -$4,489 | $5,588 |
| % Margin | -83.5% | -24.5% | -160.2% | 191.2% |
| Net Income | -$1,844 | -$637 | -$3,628 | $4,254 |
| % Margin | -71.9% | -23.9% | -129.5% | 145.6% |
| EPS Diluted | -65.36 | -21.82 | -121.79 | 140.83 |
| % Growth | -199.5% | 82.1% | -186.5% | – |
| Operating Cash Flow | $455 | $375 | $194 | $669 |
| Capital Expenditures | -$189 | -$157 | -$114 | -$134 |
| Free Cash Flow | $266 | $218 | $80 | $536 |